How should I evaluate and manage a 41-year-old female with increased hepatic echogenicity suggesting steatosis and left axillary lymph nodes measuring 1.22 cm (long axis) and 0.75 cm (short axis)?

Evaluation and Management of Hepatic Steatosis with Axillary Lymphadenopathy

This patient requires ultrasound evaluation of the axillary lymph nodes with possible biopsy if suspicious features are present, alongside metabolic risk factor assessment for MASLD.

Hepatic Steatosis Evaluation

Initial Assessment

• Increased parenchymal echogenicity most commonly indicates hepatic steatosis, but other etiologies including cirrhosis, viral hepatitis, glycogen storage disease, and hemochromatosis must be excluded 1.
• Assess for at least one cardiometabolic risk factor to establish MASLD diagnosis: BMI >25 kg/m², waist circumference >80 cm, dysglycemia/type 2 diabetes, triglycerides >150 mg/dL, HDL <50 mg/dL in women, or blood pressure >130/85 mmHg 2.
• Obtain detailed alcohol history: consumption of 20-50 g/day defines MetALD (a distinct entity with worse prognosis than MASLD), while >50 g/day indicates ALD 2.

Risk Stratification

• The stage of liver fibrosis and persistently elevated liver enzymes—not steatosis alone—determine liver-related outcomes 2.
• Check liver enzymes (ALT, AST) and consider non-invasive fibrosis assessment if cardiometabolic risk factors are present 2.
• Hyperechoic lesions ≤3 cm in patients without underlying liver disease or malignancy history are clinically insignificant in 100% of cases 3.

Quantification Considerations

• Hepatorenal index (HRI) can stratify steatosis severity: HRI ≤1.17 indicates ≤5% steatosis, while HRI ≥1.4 indicates ≥10% steatosis with >95% positive predictive value 4, 5.
• However, general population screening for steatotic liver disease is not recommended 2.

Axillary Lymph Node Evaluation

Imaging Approach

• Ultrasound is the appropriate initial imaging modality for evaluating axillary lymph nodes 2.
• The 1.22 cm long-axis measurement exceeds normal size thresholds and warrants careful sonographic characterization 2.

Sonographic Features to Assess

• Evaluate lymph node morphology: normal nodes show preserved fatty hilum, oval shape, and hilar vascularity 6.
• Suspicious features requiring biopsy include: loss of fatty hilum, rounded shape, cortical thickening >3 mm, peripheral or mixed vascularity, and heterogeneous echotexture 6.
• Benign reactive adenopathy (from infection, inflammation) typically maintains normal architecture 2.

Differential Diagnosis

• Broad differential includes: reactive adenopathy, lymphoma, leukemia, metastatic breast cancer, accessory breast tissue, lipomas, and granulomatous disease 2.
• Diagnostic mammography should be performed to exclude occult breast malignancy as the cause of lymphadenopathy 2.

Biopsy Indications

• Perform image-guided fine needle aspiration (FNA) or core needle biopsy if lymph nodes demonstrate suspicious sonographic features or lack clear benign etiology 2, 6.
• FNA and core needle biopsies are safe and accurate methods for diagnosis 6.

Clinical Pitfalls

• Do not attribute all echogenic liver findings to simple steatosis without excluding cirrhosis and other chronic liver diseases 1.
• Do not dismiss axillary lymphadenopathy as benign without proper ultrasound characterization and consideration of mammography 2.
• Recognize that MetALD (moderate alcohol consumption with metabolic risk factors) has worse prognosis than MASLD alone, making alcohol history critical 2.
• Age >60 years, cirrhosis history, and lesion size >3 cm significantly increase risk of actionable hepatic lesions requiring follow-up 3.